To study the influencing factors of chills in the treatment of Kawasaki disease with gamma globulin.

s The clinical data of 78 children with Kawasaki disease treated in our hospital from December 2017 to January 2019 were collected retrospectively. All the children were treated with gamma globulin. The children with chills were included in the chills group and the children without chills were included in the non-chills group. The general data of all the children were analyzed, and the influencing factors of chills in the treatment of Kawasaki disease with gamma globulin were analyzed.

s 23 cases of chills were found, which mainly focused on 5 min-2 h after the treatment with gamma globulin, with the time of duration of 10-50 min, the main manifestation was whole body muscle spasmodic trembling or uncontrollable contraction. The rates of age <3 years old, body mass <10 kg, history of allergy to blood products, body temperature greater than 38.5℃ before injection, injection unadjusted to room temperature in the chills group were higher than those in the non-chills group (P<0.05). Logistic multivariate analysis showed that age <3 years old, body mass <10 kg, history of allergy to blood products, body temperature greater than 38.5℃ before injection, injection unadjusted to room temperature were the risk factors of chills (OR>1, P<0.05).

Age <3 years old, body mass <10 kg, history of allergy to blood products, body temperature greater than 38.5℃ before injection, injection unadjusted to room temperature may increase the risk of chills in the course of treatment with gamma globulin. Therefore, the medical history of children should be carefully asked during clinical treatment, and attention should be paid to the drip speed and warmth of gamma globulin during treatment, so as to prevent or reduce the occurrence of chills.

Kawasaki disease; Gamma globulin; Chills; Influencing factors